Head-to-head · WeighScore
Ageless vs LillyDirect Foundayo
The verdict
Ageless takes it — 84.8/100 to 67.2/100.
Ageless grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ageless | LillyDirect Foundayo |
|---|---|---|
| WeighScore | 84.8/100 | 67.2/100 |
| Grade | B | C |
| Scorecard rank | #10 | #174 |
| Semaglutide | $119/mo | Not disclosed |
| Tirzepatide | $169/mo | Not disclosed |
| Coverage | Varies by state | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
Graded #10 · B
Strengths
- Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
- Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
- Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
- Oral routes available (drops and troches), not injection-only
Where it loses points
- Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
- Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
- No published state-availability list and no named legal entity or medical group
- Thin public track record, and advertised prices are floors set after clinical review
Graded #174 · C
Strengths
- Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- Direct from manufacturer — no compounding, no third-party reseller
- Daily oral pill, no injections, no refrigeration
- Available in all 50 states
Where it loses points
- Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- Strict empty-stomach 30-minute window may be hard for some patients to follow
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.